Kannappan Krishnaswamy, MD
Internal Medicine · Sealy, TXNPI 1700886900
Payments from drug & device makers
Across 262 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$753
- AbbVie$570
- Novo Nordisk$542
- Janssen Research & Development, LLC$500
- Merck$314
- Pfizer$214
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,18799%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 39 | $753 |
| AbbVie(2 entities) | 36 | $570 |
| Novo Nordisk | 33 | $542 |
| Janssen Research & Development, LLC | 1 | $500 |
| Merck | 26 | $314 |
| Pfizer | 18 | $214 |
| GSK | 11 | $193 |
| Johnson & Johnson | 10 | $167 |
| Dexcom, Inc. | 7 | $163 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $155 |
| Lilly USA, LLC | 9 | $137 |
| Amarin Pharma, Inc. | 7 | $134 |
| Biohaven Pharmaceuticals, Inc. | 7 | $106 |
| Sanofi-aventis U.S. LLC | 5 | $105 |
| Amgen(2 entities) | 5 | $83 |
| Esperion Therapeutics, Inc. | 5 | $77 |
| Exact Sciences | 4 | $69 |
| Boehringer Ingelheim | 4 | $63 |
| Abbott | 2 | $47 |
| Sunovion Pharmaceuticals Inc. | 4 | $42 |
| Optinose US, Inc. | 2 | $41 |
| Kowa Pharmaceuticals America, Inc. | 3 | $40 |
| Astellas Pharma US Inc | 2 | $34 |
| Novartis | 2 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| Viatris Specialty LLC | 1 | $25 |
| Nestle Healthcare Nutrition Inc. | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Bayer | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Mylan Specialty L.p. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$4,735 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 172 | $168,603 |
| FarxigaDapagliflozin Propanediol | 144 | $128,472 |
| OzempicSemaglutide | 98 | $118,322 |
| EliquisApixaban | 132 | $84,785 |
| Tresiba Flextouch U-100Insulin Degludec | 86 | $80,697 |
| TrulicityDulaglutide | 44 | $53,337 |
| LinzessLinaclotide | 75 | $51,583 |
| JanuviaSitagliptin Phosphate | 51 | $46,391 |
| MyrbetriqMirabegron | 72 | $39,226 |
| XifaxanRifaximin | 11 | $33,834 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $33,296 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 42 | $29,170 |
| TradjentaLinagliptin | 31 | $26,901 |
| Tresiba Flextouch U-200Insulin Degludec | 30 | $26,605 |
| XareltoRivaroxaban | 44 | $26,218 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $63 | $215,161227 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $753 | $166,853224 claims |
| Novo NordiskOzempic, Rybelsus | $542 | $137,136116 claims |
| PfizerEliquis | $214 | $84,785132 claims |
| MerckJanuvia, Janumet, Janumet Xr | $314 | $80,05591 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $137 | $72,39957 claims |
| AbbVieLinzess | $570 | $51,58375 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $193 | $41,88966 claims |
| Astellas Pharma US IncMyrbetriq | $34 | $39,22672 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $155 | $33,83411 claims |
| Johnson & JohnsonXarelto | $167 | $26,21844 claims |
| NovartisEntresto | $29 | $19,80112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Sealy
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.